Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

Trial Status: closed to accrual

This phase II trial tests how well vericiguat works in treating patients with breast cancer and cancer therapy-related cardiac dysfunction. Vericiguat may help improve heart (cardiac) function because it works by stimulating an enzyme, sGC, to produce a molecule called cGMP, which is necessary for normal cardiac function. By stimulating the sGC enzyme, vericiguat may help improve lung, heart, blood vessel, and muscle function. Giving vericiguat may improve cardiorespiratory fitness in patients with breast cancer and cancer therapy related cardiac dysfunction.